Identification and characterization of metallothionein-1 and -2 gene expression in the context of (±)3,4-methylenedioxymethamphetamine-induced toxicity to brain dopaminergic neurons

Journal of Neuroscience

Volumn 24, Issue 32, 2004, Pages 7043-7050

  Xie, Tao ^a   Tong, Liqiong ^a   McCann, Una D ^a   Yuan, Jie ^a   Becker, Kevin G ^b   Mechan, Annis O ^a   Cheadle, Christopher ^b   Donovan, David M ^c   Ricaurte, George A ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c AGRICULTURAL RESEARCH SERVICE   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Amphetamine; Dopamine; MDMA; Metallothioneins; Microarray; Neurotoxicity

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; COMPLEMENTARY DNA; DNA FRAGMENT; MESSENGER RNA; METALLOTHIONEIN; METALLOTHIONEIN I; METALLOTHIONEIN II; UNCLASSIFIED DRUG; ZINC ACETATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DOPAMINERGIC NERVE CELL; GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC TRANSCRIPTION; KNOCKOUT MOUSE; MALE; MESENCEPHALON; MOUSE; MT1 GENE; MT2 GENE; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; RNA TRANSLATION; WESTERN BLOTTING; WILD TYPE;

3,4-METHYLENEDIOXYAMPHETAMINE; ANIMALS; BLOTTING, NORTHERN; BRAIN; COCAINE; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; MALE; METALLOTHIONEIN; METHAMPHETAMINE; MICE; MICE, KNOCKOUT; NEURONS; NEUROPROTECTIVE AGENTS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; STREET DRUGS; TIME FACTORS;

EID: 4143146481     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1626-04.2004     Document Type: Article

References (42)

1. Asanuma M, Miyazaki I, Higashi Y, Tanaka K, Haque ME, Fujita N, Ogawa N (2002) Aggravation of 6-hydroxydopamine-induced dopaminergic lesions in metallothionein-I and -II knock-out mouse brain. Neurosci Lett 327:61-65.
2. Aschner M (1996) The function of brain metallothionein. FASEB J 10:1129-1136.
3. + release. Brain Res 813:254-261.
4. Cadet JL, Ladenheim B, Hirata H, Rothman RB, Ali S, Carlson E, Epstein C, Moran TH (1995) Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): evidence from using CuZn-superoxide dismutase transgenic mice. Synapse 21:169-176.
5. Cadet JL, Thiriet N, Jayanthi S (2001) Involvement of free radicals in MDMA-induced neurotoxicity in mice. Ann Med Interne (Paris) 152:IS57-IS59.
6. Camarero J, Sanchez V, O'Shea E, Green AR, Colado MI (2002) Studies, using in vivo microdialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4-methylenedioxymethamphetamine ("ecstasy")-induced dopamine release and free radical formation in the mouse striatum. J Neurochem 81:961-972.
7. Campagne MV, Thibodeaux H, van Bruggen N, Gerlai R, Palmer JT, William SP, Lowe DG (1999) Evidence for a protective role of metallothionein-1 in focal cerebral ischemia. Proc Natl Acad Sci USA 96:12807-12875.
8. Chung RS, West AK (2004) A role for extracellular metallothioneins in CNS injury and repair. Neuroscience 123:595-599.
9. Chung RS, Vickers JC, Chung MI, West AK (2003) Metallothionein-IIA promotes initial neurite elongation and postinjury reactive neurite growth and facilitates healing after focal cortical brain injury. J Neurosci 23:3336-3342.
10. Colado MI, Camarero J, Mechan AO, Sanchez V, Esteban B, Elliott JM, Green AR (2001) A study of the mechanism involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on dopamine neurons in mouse brain. Br J Pharmacol 134:1711-1723.
11. Dalton T, Pazdernik TL, Wagner J, Samson F, Andrews GK (1995) Temporalspatial patterns of expression of metallothionein-I and -III and other stress related genes in rat brain after kainic acid-induced seizures. Neurochem Int 27:59-71.
12. Durnam DM, Palmiter RD (1981) Transcriptional regulation of the mouse metallothionein-I gene by heavy metals. J Biol Chem 256:5712-5716.
13. Ebadi M, Ramana Kumari MV, Hiramatsu M, Hao R, Pfeiffer RF, Rojas P (1998) Metallothionein, neurotrophins and selegiline in providing neuroprotection in Parkinson's disease. Restor Neurol Neurosci 12:103-111.
14. Fuller RW, Henderson MG (1994) Neurochemistry of halogenated amphetamines. In: Amphetamine and its analogs. Psychopharmacology, toxicology and abuse (Cho AK, Segal DS, eds), pp 209-242. San Diego: Academic.
15. Fuller RW, Perry K, Molloy BB (1975) Reversible and irreversible p-chloroamphetamine serotonin depletion by 4-chloroamphetamine. Eur J Pharmacol 33:119-124.
16. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55:463-508.
17. Heffner TG, Hartman JA, Seiden LS (1980) A rapid method for the regional dissection of the rat brain. Pharmacol Biochem Behav 13:453-456.
18. Hidalgo J, Aschner M, Zatta P, Vasak M (2001) Roles of the metallothionein family of proteins in the central nervous system. Brain Res Bull 55:133-145.
19. Hussain S, Slikker Jr W, Ali SF (1996) Role of metallothionein and other antioxidants in scavenging superoxide radicals and their possible role in neuroprotection. Neurochem Int 29:145-152.
20. Jayanthi S, Ladenheim B, Andrews AM, Cadet JL (1999) Overexpression of human copper/zinc superoxide dismutase in transgenic mice attenuates oxidative stress caused by methylenedioxymethamphetamine (Ecstasy). Neuroscience 91:1379-1387.
21. Johnston LD, O'Malley PM, Bachman JG (2004) Monitoring the future national results on adolescent drug use: overview of key findings, 2003. NIH publication number 04-5506. Bethesda, MD: National Institute on Drug Abuse.
22. Kawashima T, Doh K, Torisu M, Uchida Y, Furuta A, Iwaki T (2000) Differential expression of metallothioneins in human prion diseases. Dement Geriatr Cogn Disord 11:251-262.
23. Lane LC (1978) A simple method for stabilizing protein-sulfhydryl groups during SDS-gel electrophoresis. Anal Biochem 86:655-664.
24. Lazo JS, Kondo Y, Dellapiazza D, Michalska AE, Choo KHA, Pitt BR (1995) Enhanced sensitivity to oxidative stress in cultured embryonic cells from transgenic mice deficient in metallothionein I and II genes. J Biol Chem 270:5506-5510.
25. Logan BJ, Laverty R, Sanderson WD, Yee YB (1988) Differences between rats and mice in MDMA (methylenedioxymethylamphetamine) neurotoxicity. Eur J Pharmacol 152:227-234.
26. Meek JL, Fuxe K, Carlsson A (1971) Blockade of p-chloromethamphetamine induced 5-hydroxytryptamine depletion by chlorimipramine, chlorpheniramine and meperidine. Biochem Pharmacol 20:707-709.
27. O'Callaghan JP, Miller DB (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270:741-751.
28. O'Shea E, Esteban B, Camarero J, Green AR, Colado MI (2001) Effect of GBR12909 and fluoxetine on the acute and long term changes induced by MDMA ("ecstasy") on the 5-HT and dopamine concentrations in mouse brain. Neuropharmacology 40:65-74.
29. Penkowa M, Hidalgo J (2000) Metallothionein I+II expression and their role in experimental autoimmune encephalomyelitis. Glia 32:247-263.
30. Penkowa M, Hidalgo J (2001) Metallothionein treatment reduces proinflammatory cytokines IL-6 and TNF-alpha and apoptotic cell death during experimental autoimmune encephalomyelitis (EAE). Exp Neurol 170:1-14.
31. Penkowa M, Hidalgo J (2003) Treatment with metallothionein prevents demyelination and axonal damage and increases oligodendrocyte precursors and tissue repair during experimental autoimmune encephalomyelitis. J Neurosci Res 72:574-586.
32. Penkowa M, Carrasco J, Giralt M, Moos T, Hidalgo J (1999) CNS wound healing is severely depressed in metallothionein I- and II-deficient mice. J Neurosci 19:2535-2545.
33. Penkowa M, Carrasco J, Giralt M, Molinero A, Hernandez J, Campbell IL, Hidalgo J (2000) Altered central nervous system cytokine-growth factor expression profiles and angiogenesis in metallothionein-I + II deficient mice. J Cereb Blood Flow Metab 20:1174-1189.
34. Penkowa M, Giralt M, Thomsen PS, Carrasco J, Hidalgo J (2001) Zinc or copper deficiency-induced impaired inflammatory response to brain trauma may be caused by the concomitant metallothionein changes. J Neurotrauma 18:447-463.
35. Ricaurte GA, Martello AL, Katz JL, Martello MB (1992) Lasting effects of (±)3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther 261:616-622.
36. Rojas P, Klaassen CD (1999) Metallothionein-I and -II knock-out mice are not more sensitive than control mice to 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. Neurosci Lett 273:113-116.
37. Rojas P, Rios C (1997) Metallothionein inducers protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice. Neurochem Res 22:17-22.
38. Schmidt CJ (1987) Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 240:1-7.
39. Tanaka TS, Jaradat SA, Lim MK, Kargul GJ, Wang X, Grahovac MJ, Pantano S, Sano Y, Piao Y, Nagaraja R, Doi H, Wood III WH, Becker KG, Ko MS (2000) Genome-wide expression profiling of mid-gestation placenta and embryo using a 15,000 mouse developmental cDNA microarray. Proc Natl Acad Sci USA 97:9127-9132.
40. Vawter MP, Barrett T, Cheadle C, Sokolov BP, Wood WH, Donovan D, Webster M, Freed WJ, Becker KG (2001) Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Res Bull 55:641-650.
41. Wijsman JA, Shivers RR (1993) Heat stress affects blood-brain barrier permeability to horseradish peroxidase in mice. Acta Neuropathol 86:49-54.
42. Xie T, Tong L, Barrett T, Yuan J, Hatzidimitriou G, McCann UD, Becker KG, Donovan DM, Ricaurte GA (2002) Changes in gene expression linked to methamphetamine-induced dopaminergic neurotoxicity. J Neurosci 22:274-283.